vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and ROGERS CORP (ROG). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $200.5M, roughly 1.7× ROGERS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs 2.2%, a 11.0% gap on every dollar of revenue. On growth, ROGERS CORP posted the faster year-over-year revenue change (5.2% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $1.1M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -3.3%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
HAE vs ROG — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $200.5M |
| Net Profit | $44.7M | $4.5M |
| Gross Margin | 59.7% | 32.2% |
| Operating Margin | 19.9% | — |
| Net Margin | 13.2% | 2.2% |
| Revenue YoY | -2.7% | 5.2% |
| Net Profit YoY | 19.3% | 421.4% |
| EPS (diluted) | $0.95 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $339.0M | $201.5M | ||
| Q3 25 | $327.3M | $216.0M | ||
| Q2 25 | $321.4M | $202.8M | ||
| Q1 25 | $330.6M | $190.5M | ||
| Q4 24 | $348.5M | $192.2M | ||
| Q3 24 | $345.5M | $210.3M | ||
| Q2 24 | $336.2M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $44.7M | $4.6M | ||
| Q3 25 | $38.7M | $8.6M | ||
| Q2 25 | $34.0M | $-73.6M | ||
| Q1 25 | $58.0M | $-1.4M | ||
| Q4 24 | $37.5M | $-500.0K | ||
| Q3 24 | $33.8M | $10.7M | ||
| Q2 24 | $38.4M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 59.7% | 31.5% | ||
| Q3 25 | 59.5% | 33.5% | ||
| Q2 25 | 59.8% | 31.6% | ||
| Q1 25 | 58.4% | 29.9% | ||
| Q4 24 | 55.5% | 32.1% | ||
| Q3 24 | 54.2% | 35.2% | ||
| Q2 24 | 52.0% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 19.9% | 3.5% | ||
| Q3 25 | 17.9% | 7.3% | ||
| Q2 25 | 16.8% | -33.3% | ||
| Q1 25 | 21.6% | -0.2% | ||
| Q4 24 | 16.9% | -6.6% | ||
| Q3 24 | 15.0% | 6.9% | ||
| Q2 24 | 11.8% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 13.2% | 2.3% | ||
| Q3 25 | 11.8% | 4.0% | ||
| Q2 25 | 10.6% | -36.3% | ||
| Q1 25 | 17.5% | -0.7% | ||
| Q4 24 | 10.8% | -0.3% | ||
| Q3 24 | 9.8% | 5.1% | ||
| Q2 24 | 11.4% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.95 | $0.20 | ||
| Q3 25 | $0.81 | $0.48 | ||
| Q2 25 | $0.70 | $-4.00 | ||
| Q1 25 | $1.17 | $-0.08 | ||
| Q4 24 | $0.74 | $-0.04 | ||
| Q3 24 | $0.66 | $0.58 | ||
| Q2 24 | $0.74 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $195.8M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $1.2B |
| Total Assets | $2.5B | $1.4B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $363.4M | $197.0M | ||
| Q3 25 | $296.4M | $167.8M | ||
| Q2 25 | $292.9M | $157.2M | ||
| Q1 25 | $306.8M | $175.6M | ||
| Q4 24 | $320.8M | $159.8M | ||
| Q3 24 | $299.3M | $146.4M | ||
| Q2 24 | $344.4M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $911.5M | $1.2B | ||
| Q3 25 | $849.2M | $1.2B | ||
| Q2 25 | $882.3M | $1.2B | ||
| Q1 25 | $820.8M | $1.3B | ||
| Q4 24 | $906.9M | $1.3B | ||
| Q3 24 | $878.9M | $1.3B | ||
| Q2 24 | $905.4M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.5B | $1.4B | ||
| Q3 25 | $2.4B | $1.4B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.5B | $1.5B | ||
| Q4 24 | $2.5B | $1.5B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $5.8M |
| Free Cash FlowOCF − Capex | $87.2M | $1.1M |
| FCF MarginFCF / Revenue | 25.7% | 0.5% |
| Capex IntensityCapex / Revenue | 1.9% | 2.3% |
| Cash ConversionOCF / Net Profit | 2.09× | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $93.6M | $46.9M | ||
| Q3 25 | $111.3M | $28.9M | ||
| Q2 25 | $17.4M | $13.7M | ||
| Q1 25 | $116.6M | $11.7M | ||
| Q4 24 | $43.8M | $33.7M | ||
| Q3 24 | $48.8M | $42.4M | ||
| Q2 24 | $-27.4M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $87.2M | $42.2M | ||
| Q3 25 | $106.3M | $21.2M | ||
| Q2 25 | $13.6M | $5.6M | ||
| Q1 25 | $100.9M | $2.1M | ||
| Q4 24 | $35.2M | $18.3M | ||
| Q3 24 | $39.4M | $25.2M | ||
| Q2 24 | $-33.1M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 25.7% | 20.9% | ||
| Q3 25 | 32.5% | 9.8% | ||
| Q2 25 | 4.2% | 2.8% | ||
| Q1 25 | 30.5% | 1.1% | ||
| Q4 24 | 10.1% | 9.5% | ||
| Q3 24 | 11.4% | 12.0% | ||
| Q2 24 | -9.8% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.9% | 2.3% | ||
| Q3 25 | 1.5% | 3.6% | ||
| Q2 25 | 1.2% | 4.0% | ||
| Q1 25 | 4.7% | 5.0% | ||
| Q4 24 | 2.5% | 8.0% | ||
| Q3 24 | 2.7% | 8.2% | ||
| Q2 24 | 1.7% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 2.09× | 10.20× | ||
| Q3 25 | 2.88× | 3.36× | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | 3.96× | ||
| Q2 24 | -0.71× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
ROG
Segment breakdown not available.
